COMPANY · NIPC 502593687
BANCO BILBAO VIZCAYA ARGENTARIA (PORTUGAL) S.A.
This page shows the public contracts the company has signed, which bodies gave them, and who it competed against.
Portal BASE records €1,354,531.24 across 4 contracts.
Identification
| Company name | BANCO BILBAO VIZCAYA ARGENTARIA (PORTUGAL) S.A. |
|---|---|
| NIPC | 502593687 |
| Registered office | AVENIDA DA LIBERDADE, N.º 222, SANTO ANTÓNIO, 1250-148 LISBON |
| Source | GLEIF (LEI), registo 549300QD1160SR6LNZ76 |
| Record date | 27 October 2026 |
Contracted money
Sums of the contract prices on Portal BASE. A contract with several buyers or municipalities counts once in each row, so rows do not add up to the total.
| Year | Contracts | Contract value |
|---|---|---|
| 2017 | 1 | €274,828.50 |
| 2018 | 1 | €431,794.80 |
| 2023 | 2 | €647,907.94 |
| Name | Contracts | Contract value |
|---|---|---|
| Unidade Local de Saúde de Braga, E. P. E. | 2 | €647,907.94 |
| Centro Hospitalar de Setúbal, E. P. E. | 1 | €431,794.80 |
| Centro Hospitalar Lisboa Norte, E. P. E. | 1 | €274,828.50 |
| Name | Contracts | Contract value |
|---|---|---|
| Braga | 2 | €647,907.94 |
| Setúbal | 1 | €431,794.80 |
| Lisboa | 1 | €274,828.50 |
| Subject | Year | Contract value |
|---|---|---|
| Aquisição de Teclistamab 90 mg/ml Sol inj Fr 1.7 ml SC | 2023 | €439,598.44 |
| DARUNAVIR 800 MG + COBICISTATE 150 MG COMP | 2018 | €431,794.80 |
| Aquisição de ibrutinib 140 mg caps. | 2017 | €274,828.50 |
| Aquisição de Daratumumab 1800 mg/15 ml Sol inj Fr SC | 2023 | €208,309.50 |
Who they competed with
The IMPIC files list no competitors for this company's contracts.
The annual IMPIC file lists competitors for about 42% of contracts. Only these enter the counts, and the award share is measured on them.
Links read in contract documents
Contract documents give addresses and the names of representatives and partners, and Portal BASE and GLEIF give competitors and groups. This is what the records show; the same address or name can have simple explanations.
The documents we read show no links between these companies.
Investigations that mention it
No published investigation mentions this company by NIPC.